EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Alpha‐synuclein co‐pathology in Down syndrome‐associated Alzheimer's disease

Alexander Maximilian Bernhardt, Íñigo Rodríguez-Baz iD, Iban Aldecoa, Javier Arranz, José Enrique Arriola-Infante, Lucia Maure-Blesa, Maria Carmona-Iragui, Sebastian Longen, Svenja Verena Trossbach, Armin Giese, Torsten Matthias, Bessy Benejam und 18 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Alexander Maximilian Bernhardt und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, alpha-Synuclein, Down Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ajuntament de Barcelona, in collaboration with Fundació La Caixa, Anton and Petra Ehrmann-Stiftung, German Ministry of Research and Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Alpha‐synuclein (αSyn) seed amplification assay (SAA) enables in vivo study of αSyn but remains underexplored in Down syndrome‐associated Alzheimer's disease (DSAD). METHODS We analyzed αSyn‐SAA in cerebrospinal fluid (CSF) from 270 adults with Down syndrome, from the Down Alzheimer Barcelona Neuroimaging Initiative and from the AD21 cohort from the Department of Neurology at the University Hospital, Ludwig Maximilian University of Munich, Germany. Neuropathological examinations were conducted in 19 brain donors (five with ante mortem CSF). Participants were classified as asymptomatic or symptomatic (prodromal/dementia) Alzheimer's disease (AD). CSF Aβ1‐42/1‐40, CSF and plasma p‐Tau181, and neurofilament light chain (NfL) levels were measured. Neuropathological evaluations assessed AD neuropathological changes and Lewy body pathology (LBP). RESULTS ΑSyn‐SAA was positive in 9.2% of cases, independent of age or cognitive status. Symptomatic αSyn‐positive cases exhibited higher plasma NfL levels than αSyn‐negative cases (31 vs 21 pg/mL, p = 0.027). LBP was observed in 47% of necropsies. The individual with severe neocortical LBP was αSyn‐SAA‐positive. DISCUSSION These findings highlight LBP prevalence in DSAD but suggest current SAA may fail to detect limited αSyn deposition. Highlights αSyn‐SAA positivity in DSAD is 9.2%, similar to ADAD but lower than sporadic AD. Misfolded αSyn was detectable from early ages in individuals with DS. Positivity rates did not vary with age or clinical status in DS. Plasma NfL levels are higher in symptomatic αSyn‐SAA positive versus negative cases. CSF αSyn seeding activity was associated with high neocortical LBP at necropsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer Diseasealpha-SynucleinDown SyndromeHumansFemaleMaleMiddle AgedAgedAmyloid beta-PeptidesBrainBiomarkerstau ProteinsAdultNeurofilament Proteins

Stichwörter der Autor:innen

Alzheimer's diseaseDown syndromeLewy body pathologybiomarkerneuropathologyseed amplification assayα‐synuclein

Substanzen

alpha-SynucleinAmyloid beta-PeptidesBiomarkerstau ProteinsNeurofilament Proteins

Autor:innen und Institutionen

  • Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), site Munich, Munich, Germany.
  • Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain.
  • Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Neurological Tissue Bank of the Biobanc, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS/FCRB), Hospital Clinic, Barcelona, Spain.
  • Pathology Department, Biomedical Diagnostic Center, Hospital Clinic de Barcelona-University of Barcelona, Barcelona, Spain.

ORCID-Profile: Íñigo Rodríguez-Baz

Förderung

  • Ajuntament de Barcelona, in collaboration with Fundació La Caixa
  • Anton and Petra Ehrmann-Stiftung
  • German Ministry of Research and Education
  • Deutsche Forschungsgemeinschaft
  • Fondation Jérôme Lejeune
  • the BrightFocus Foundation
  • Horizon 2020 Framework Programme, MESCOBRAD
  • Fundación Tatiana Pérez de Guzmán el Bueno

Zitieren

APA

Bernhardt, A. M., Rodríguez-Baz, Í., Aldecoa, I., Arranz, J., Arriola-Infante, J. E., Maure-Blesa, L., Carmona-Iragui, M., Longen, S., Trossbach, S. V., Giese, A., Matthias, T., Benejam, B., Videla, L., Del Hoyo Soriano, L., Barroeta, I., Sanjuan, A., Fernández, S., Vaqué-Alcázar, L., Rozalem Aranha, M., …, & Levin, J. (2025). Alpha‐synuclein co‐pathology in Down syndrome‐associated Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70342

Vancouver

Bernhardt AM, Rodríguez-Baz Í, Aldecoa I, Arranz J, Arriola-Infante JE, Maure-Blesa L, et al. Alpha‐synuclein co‐pathology in Down syndrome‐associated Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70342

BibTeX
@article{Bernhardt2025,
  author = {Bernhardt, Alexander Maximilian and Rodríguez-Baz, Íñigo and Aldecoa, Iban and Arranz, Javier and Arriola-Infante, José Enrique and Maure-Blesa, Lucia and Carmona-Iragui, Maria and Longen, Sebastian and Trossbach, Svenja Verena and Giese, Armin and Matthias, Torsten and Benejam, Bessy and Videla, Laura and Del Hoyo Soriano, Laura and Barroeta, Isabel and Sanjuan, Aída and Fernández, Susana and Vaqué-Alcázar, Lídia and Rozalem Aranha, Mateus and Morcillo-Nieto, Alejandra O and Nübling, Georg and Wagemann, Olivia and Stockbauer, Anna and Tondo, Mireia and Bejanin, Alexandre and Lleó, Alberto and Alcolea, Daniel and Molina-Porcel, Laura and Fortea, Juan and Levin, Johannes},
  title = {Alpha‐synuclein co‐pathology in Down syndrome‐associated Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70342}
}
Kostenlos starten →